journal article·2015-01Open access

Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity

Ping-Lun Jiang, Hung-Jun Lin, Hsiao-Wen Wang, Wen-Yu Tsai, Shen-Fu Lin, Mei-Yin Chien, Pi-Hui Liang, Yi-You Huang, Der-Zen Liu

Acta Biomaterialia· Volume 11

Abstract

Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens and mount protective immunity. We previously demonstrated that intranasal administration of targeted galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that mediated by unmodified liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced higher levels of pro-inflammatory cytokines than unmodified liposomes in vitro. C57BL/6 mice thrice immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high levels of OVA-specific IgG antibodies in their serum. Spleen cells from mice receiving galactosylated liposomes were restimulated with OVA and showed significantly augmented levels of IFN-γ, IL-4, IL-5 and IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indicate that nasal administration of a galactosylated liposome vaccine mediates the development of an effective immunity against tumors and might be useful for further clinical anti-tumoral applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer’s patches: a mechanism for antigen sampling and for microbial transepithelial migration10.1093/infdis/153.6.1108 ↗
2. Antigen transport into Peyer’s patches: increased uptake by constant numbers of M cells10.1016/S0002-9440(10)63097-0 ↗
4. Dendritic cells and the control of immunity10.1038/32588 ↗
5. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design10.1016/j.smim.2007.11.007 ↗
6. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model10.1111/j.1365-2567.2009.03237.x ↗
7. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity10.1073/pnas.96.8.4512 ↗
8. Mucosal immunization with liposome–nucleic acid adjuvants generates effective humoral and cellular immunity10.1016/j.vaccine.2011.05.009 ↗
9. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract10.1208/s12249-007-9021-9 ↗
10. Immunological adjuvants: a role for liposomes10.1016/0167-5699(90)90034-7 ↗
11. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN10.1016/j.ejpb.2006.05.005 ↗
12. Intranasal immunization of humans with Streptococcus mutans antigens10.1034/j.1399-302X.2003.00067.x ↗
13. Topical and mucosal liposomes for vaccine delivery10.1002/wnan.131 ↗
14. The influence of liposomal adjuvant on intranasal vaccination of chickens against Newcastle disease10.1016/j.tvjl.2009.05.019 ↗
15. Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens10.1016/j.biomaterials.2009.06.046 ↗
16. DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease10.1111/j.0300-9475.2004.01431.x ↗
17. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity10.1016/j.jconrel.2008.03.023 ↗
18. C-type lectin receptors on dendritic cells and Langerhans cells10.1038/nri723 ↗
19. Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL110.1074/jbc.M203774200 ↗
20. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation10.1189/jlb.0304212 ↗
21. Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigens10.1093/glycob/cwf061 ↗
22. The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells10.1074/jbc.M202104200 ↗
23. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization10.1016/j.actbio.2012.11.007 ↗
24. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor10.1084/jem.176.6.1693 ↗
25. Isolation and characterization of mouse nasal-associated lymphoid tissue10.1016/S0022-1759(96)00243-8 ↗
26. The role of nasopharyngeal lymphoid tissue10.1016/0167-5699(92)90158-4 ↗
27. Collaboration of epithelial cells with organized mucosal lymphoid tissues10.1038/ni1101-1004 ↗
28. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue10.1128/IAI.66.12.5876-5881.1998 ↗
29. Novel vaccine development strategies for inducing mucosal immunity10.1586/erv.11.196 ↗
30. Liposome-mediated peptide loading of MHC-DR molecules in vivo10.1016/S0014-5793(97)00493-6 ↗
31. New generation of mucosal adjuvants for the induction of protective immunity10.1002/rmv.398 ↗
32. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems10.1016/j.jconrel.2010.08.012 ↗
33. Self- and nonself-recognition by C-type lectins on dendritic cells10.1146/annurev.immunol.22.012703.104558 ↗
34. C-type lectins on dendritic cells: key modulators for the induction of immune responses10.1042/BST0361478 ↗
35. Tolerizing allergic responses in the lung10.1038/mi.2010.19 ↗
36. T-cell regulation by CD28 and CTLA-410.1038/35105024 ↗
37. Immunobiology of dendritic cells10.1146/annurev.immunol.18.1.767 ↗
38. Dendritic cell lineage, plasticity and cross-regulation10.1038/89726 ↗
39. The effects of IL-6 on CD4 T cell responses10.1016/j.clim.2008.08.018 ↗
40. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity10.1146/annurev.iy.13.040195.001343 ↗
41. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization10.1007/s10719-009-9263-8 ↗
42. Introduction of soluble protein into the class I pathway of antigen processing and presentation10.1016/S0092-8674(88)91043-4 ↗
43. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors10.1126/scitranslmed.3004888 ↗